Trial Profile
A Study of Apatinib Monotherapy as the Salvage Treatment in Advanced/Recurrent Gynaecological Cancer Patients who Failed from Two or More Lines of Prior Chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Cervical cancer; Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
- 14 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.